Skip to content
GLP-1 Scorecard
Menu

Head-to-head · WeighScore

GoodRx vs Rebody Health

GoodRx
Graded #122

Higher grade

vs+1.8999999999999915
Rebody Health
Graded #162

Lower grade

The verdict

GoodRx takes it — 69.6/100 to 67.7/100, but only just.

GoodRx grades higher on WeighScore, our editorial score across cost value, dose & formulation, clinical oversight, labs & monitoring, fulfillment and contract terms. GoodRx (NASDAQ: GDRX) is the largest US prescription savings platform. Rebody Health is close behind and may still be the better fit — see the factor split below.

We may earn a commission if you start care through some of these links, at no extra cost to you. It never moves the WeighScore, which is the weighted average of the six factors shown for every provider, and what we write about a provider is the same either way. See our disclosure.

Factor by factor

The same six graded dimensions, side by side. See the methodology.

Cost valueGoodRx +34
80
46
Dose & formulationRebody Health +18
70
88
Clinical oversightRebody Health +12
69
81
Labs & monitoringRebody Health +2
51
53
FulfillmentRebody Health +3
81
84
Contract termsEven
55
55
GoodRx · left barRebody Health · right bar

The numbers

MetricGoodRxRebody Health
WeighScore69.6/10067.7/100
GradeCC
Scorecard rank#122#162
SemaglutideNot disclosed$200/mo (starting dose, compounded)
Tirzepatide$299/mo (brand Zepbound)$250/mo (starting dose, compounded)
CoverageAll 50 states47 states
Brand-name accessYesYes
Oral / sublingualInjection onlyYes
GoodRx

Graded #122 · C

Strengths

  • $149/month self-pay for brand-name Foundayo (orforglipron) — matches the lowest cash price at launch, far below typical retail
  • $299/month self-pay for Zepbound KwikPen — well under Lilly's typical cash list price
  • Honored at 70,000+ US pharmacies — the largest retail redemption network of any GLP-1 channel we cover
  • No membership fee — bring your own prescription and present the discount card at the pharmacy counter
  • Brand-name FDA-approved medication, not compounded

Where it loses points

  • Requires a valid prescription — GoodRx is a discount card, not a prescriber; you still need a clinician to write the script
  • Self-pay only — does not apply toward insurance benefits or deductibles
  • Headline price applies to the lowest Foundayo dose; higher doses may cost more
  • No compounded GLP-1 options — not the channel for compounded semaglutide or tirzepatide
  • Pricing can change as Lilly's manufacturer coupon program evolves
Rebody Health

Graded #162 · C

Strengths

  • Publishes transparent, dose-based pricing up front on a public pricing page, so you can see costs without signing up
  • Offers compounded semaglutide and tirzepatide as both weekly injections and daily oral 'melt' tablets
  • Also carries brand-name Wegovy and Zepbound for patients who want FDA-approved products
  • Clear plan-term vs dose-tier structure; the refill price is shown before each shipment, plus $50 off the first month
  • Names its operating company (Compound Technologies Inc.) and references LegitScript approval

Where it loses points

  • Individual compounding pharmacies are not named on the marketing site
  • Not available in Massachusetts, Rhode Island, or Vermont
  • Compounded semaglutide and tirzepatide are not FDA-approved finished products
  • Dose-scaled pricing means the monthly cost can rise as your prescribed dose increases

Also worth a look

Neither is our top-graded pick — CoreAge Rx leads the scorecard

Across all 499 providers, CoreAge Rx grades highest at 91.8/100 (A−). Top of the scorecard: flat transparent pricing, both molecules, nationwide — no teaser-rate games.

Pricing/verification reflect each provider's public disclosures at last grading; the WeighScore is our editorial judgment per the methodology. Prices change — confirm on each provider's site. Not medical advice; see our disclosure.

← Back to the scorecard